PEPT-IN Trademark

Trademark Overview

On Friday, July 10, 2020, a trademark application was filed for PEPT-IN with the United States Patent and Trademark Office. The USPTO has given the PEPT-IN trademark a serial number of 79293682. The federal status of this trademark filing is ABANDONED - AFTER EX PARTE APPEAL as of Thursday, December 14, 2023. This trademark is owned by AELIN THERAPEUTICS N.V.. The PEPT-IN trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical and veterinary products, namely, pharmaceutical products and medications made of peptides for inducing protein aggregation in the treatment of cancer and infectious diseases and synthetic peptides as pharmaceutical products and medications for inducing protein aggregation in the treatment of cancer and infectious diseases; all of the foregoing commercialized through a select network of clinicians who administer the products and medications in a hospital setting or available through prescription by a clinician

Scientific and technological services and research and design relating thereto, namely, pharmaceutical research and development of peptide-based pharmaceutical products and medicines and pharmaceutical research and development of pharmaceutical products and medicines on the basis of protein aggregation stimulating peptides
pept-in

General Information

Serial Number79293682
Word MarkPEPT-IN
Filing DateFriday, July 10, 2020
Status603 - ABANDONED - AFTER EX PARTE APPEAL
Status DateThursday, December 14, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical and veterinary products, namely, pharmaceutical products and medications made of peptides for inducing protein aggregation in the treatment of cancer and infectious diseases and synthetic peptides as pharmaceutical products and medications for inducing protein aggregation in the treatment of cancer and infectious diseases; all of the foregoing commercialized through a select network of clinicians who administer the products and medications in a hospital setting or available through prescription by a clinician
Goods and ServicesScientific and technological services and research and design relating thereto, namely, pharmaceutical research and development of peptide-based pharmaceutical products and medicines and pharmaceutical research and development of pharmaceutical products and medicines on the basis of protein aggregation stimulating peptides

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 25, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 25, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAELIN THERAPEUTICS N.V.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBE

Trademark Events

Event DateEvent Description
Friday, December 15, 2023ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Friday, December 15, 2023ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Thursday, December 14, 2023ABANDONMENT - AFTER EX PARTE APPEAL
Thursday, December 14, 2023EXPARTE APPEAL TERMINATED
Monday, October 30, 2023EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF
Wednesday, August 16, 2023NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Wednesday, August 16, 2023ACTION DENYING REQ FOR RECON E-MAILED
Wednesday, August 16, 2023ACTION CONTINUING FINAL - COMPLETED
Friday, November 18, 2022SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Saturday, April 2, 2022NEW REPRESENTATIVE AT IB RECEIVED
Friday, April 1, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, April 1, 2022LETTER OF SUSPENSION E-MAILED
Friday, April 1, 2022SUSPENSION LETTER WRITTEN
Sunday, March 13, 2022NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, February 23, 2022NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, February 23, 2022NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, January 26, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 26, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 26, 2022ASSIGNED TO LIE
Friday, January 21, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, January 20, 2022EX PARTE APPEAL-INSTITUTED
Thursday, January 20, 2022JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, January 20, 2022EXPARTE APPEAL RECEIVED AT TTAB
Friday, July 30, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, July 30, 2021FINAL REFUSAL E-MAILED
Friday, July 30, 2021FINAL REFUSAL WRITTEN
Sunday, July 4, 2021ASSIGNED TO EXAMINER
Monday, April 26, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 26, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, April 2, 2021NEW REPRESENTATIVE AT IB RECEIVED
Sunday, December 6, 2020REFUSAL PROCESSED BY IB
Friday, November 13, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, November 13, 2020REFUSAL PROCESSED BY MPU
Tuesday, October 27, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, October 26, 2020NON-FINAL ACTION WRITTEN
Thursday, October 22, 2020ASSIGNED TO EXAMINER
Tuesday, September 29, 2020APPLICATION FILING RECEIPT MAILED
Friday, September 25, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 22, 2020LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, September 17, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

pept pharmaceutical products aggregation peptides medications protein research medicines development diseases